Martina Gaia Di Donna

Martina Gaia Di Donna

Auto-generated profile, based on publicly available information

Martina Gaia Di Donna

Memory Clinic and Neurodegenerative Dementia Research Unit University of Rome “Tor Vergata” Rome Italy

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2022 in Stroke
Verified
Journal Article
Closed access
PDF file
VLValentina Longo
Valentina Longo
SBSaviana Antonella Barbati
Saviana Antonella Barbati
ARAgnese Re
Agnese Re
FPFabiola Paciello
Fabiola Paciello
MBMaria Bolla
Maria Bolla
Claudio GrassiClaudio Grassi
Claudio Grassi
Background: More effective strategies are needed to promote poststroke functional recovery. Here, we evaluated the impact of bihemispheric transcranial direct current stimulation (tDCS) on forelimb motor function recovery and the underlying mechanisms in mice subjected to focal ischemia of the motor cortex. Methods: Photothrombotic stroke was induced in the forelimb brain motor area, and tDCS was applied once per day for 3 consecutive days, starting 72 hours after stroke. Grid-walking, single pellet reaching, and grip strength tests were conducted to assess motor function. Local field potentials were recorded to evaluate brain connectivity. Western immunoblotting, ELISA, quantitative real-time polymerase chain reaction, and Golgi-Cox staining were used to uncover tDCS-mediated stroke recovery mechanisms. Results: Among our results, tDCS increased the rate of motor recovery, anticipating it at the early subacute stage. In this window, tDCS enhanced BDNF (brain-derived neurotrophic factor) expression and dendritic spine density in the peri-infarct motor cortex, along with increasing functional connectivity between motor and somatosensory cortices. Treatment with the BDNF TrkB (tropomyosin-related tyrosine kinase B) receptor inhibitor, ANA-12, prevented tDCS effects on motor recovery and connectivity as well as the increase of spine density, pERK (phosphorylated extracellular signal-regulated kinase), pCaMKII (phosphorylated calcium/calmodulin-dependent protein kinase II), pMEF (phosphorylated myocyte-enhancer factor), and PSD (postsynaptic density)-95. The tDCS-promoted rescue was paralleled by enhanced plasma BDNF level, suggesting its potential role as circulating prognostic biomarker. Conclusions: The rate of motor recovery is accelerated by tDCS applied in the subacute phase of stroke. Anticipation of motor recovery via vicariate pathways or neural reserve recruitment would potentially enhance the efficacy of standard treatments, such as physical therapy, which is often delayed to a later stage when plastic responses are progressively lower.

Verified
Journal Article
Open access
PDF file
Riccardo CameddaRiccardo Camedda
Riccardo Camedda
CBChiara Giuseppina Bonomi
Chiara Giuseppina Bonomi
MDMartina Gaia Di Donna
Martina Gaia Di Donna
ACAgostino Chiaravalloti
Agostino Chiaravalloti
The aim of our study was to investigate regional glucose metabolism with 18F-FDG positron emission tomography/computed tomography in a population of patients with Alzheimer’s disease (AD) in relation to cerebrospinal (CSF) levels of striatal dopamine transporter (DAT). All patients underwent lumbar puncture and received a biomarker-based diagnosis of AD. Differences in regional brain glucose metabolism were assessed by Statistical Parametric Mapping version 12 with the use of age, gender, and MMSE as covariates in the analysis. A positive correlation between CSF DAT levels and glucose metabolism at the level of two brain areas involved in the pathophysiological process of Alzheimer’s disease, the substantia nigra and the posterior cingulate gyrus, has been highlighted. Results indicate that patients with higher CSF DAT levels have a better metabolic pattern in two key zones, suggesting less advanced disease status in patients with more conserved dopaminergic systems.

2 November 2024 in Neurology and Therapy
Verified
Journal Article
Open access
PDF file
Alessandro MartoranaAlessandro Martorana
Alessandro Martorana
CBChiara Giuseppina Bonomi
Chiara Giuseppina Bonomi
MDMartina Gaia Di Donna
Martina Gaia Di Donna
CMCaterina Motta
Caterina Motta
Lecanemab (Leqembi©, Biogen), a humanized anti-amyloid-beta monoclonal antibody, has been approved for early-stage Alzheimer’s disease (AD) in several countries, including the US and Japan. However, the European Medicines Agency (EMA) recently issued a negative opinion on its marketing authorization, reflecting concerns over the clinical value and manageability of anti-amyloid treatments. This decision highlights the ongoing disconnect between research advancements and clinical practice, where the focus on biological markers over tangible clinical improvements remains contentious. Despite promising biological effects, lecanemab’s clinical outcomes have been modest, raising questions about its therapeutic role. The EMA’s refusal underscores the need to address doubts surrounding the real-world effectiveness and safety of such treatments, especially concerning amyloid-related imaging abnormalities (ARIAs), a common side effect observed in clinical trials. The recent approval of lecanemab by the UK's Medicines and Healthcare products Regulatory Agency, despite the National Institute for Health and Care Excellence’s rejection on cost-effectiveness grounds, further fuels the debate on the feasibility of anti-amyloid therapies. This commentary emphasizes the importance of real-world data on lecanemab's impact on cognitive decline, daily functioning, and side-effect management. As the global clinical use of lecanemab increases, continuous and standardized reporting on its outcomes is crucial for guiding future regulatory decisions and for potentially bridging the gap between research and practice in AD treatment.

1 June 2026 in Stroke
Verified
Journal Article
Closed access
MBMaria Rosaria Bagnato
Maria Rosaria Bagnato
FBFrancesca Bernocchi
Francesca Bernocchi
GMGiovanni Di Mauro
Giovanni Di Mauro
CSCarlo Emanuele Saggese
Carlo Emanuele Saggese
MDMartina Gaia Di Donna
Martina Gaia Di Donna

5 June 2026 in Neurological Sciences
Verified
Journal Article
Closed access
MBMaria Rosaria Bagnato
Maria Rosaria Bagnato
MDMartina Gaia Di Donna
Martina Gaia Di Donna
FBFrancesca Bernocchi
Francesca Bernocchi
LBLaura Borrello
Laura Borrello
MBMartina Bracaglia
Martina Bracaglia
RSRoberto De Simone
Roberto De Simone

6 January 2025 in Neurological Sciences
Verified
Journal Article
Closed access
PDF file
Francesco GruossoFrancesco Gruosso
Francesco Gruosso
VFValerio Ferrari
Valerio Ferrari
MDMartina Di Donna
Martina Di Donna
MFMario Ferrante
Mario Ferrante
MBMaria Rosaria Bagnato
Maria Rosaria Bagnato